Clinical trials: Standard Care Control
Lymphocyte Depletion
Lymphocyte Depletion and Change in Lymphocyte Functionality
Lymphocytes are a type of white blood cell (WBC) responsible for adaptive immunity. Thoracic tumors are adjacent to many blood/immune rich organs including the great vessels, heart, thoracic-spine, and lymph-node-stations.
- Trial name
- NCT04273893
- Testing
- SBRT with additional treatment planning dose optimization, SBRT with standard of care planning only, Blood Draws
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Virginia
Mastodynia
A Breast Support Intervention for Women With Breast Pain
The purpose of this study is to assess whether prescribing a bra to participants results in an improvement in the Patient Global Impression of Change (PGIC) compared to participants who receive standard care alone.
- Trial name
- NCT02515253
- Testing
- Bra prescription, Standard Care
- Where
- 2 sites in United Kingdom
- Volunteers
- 33 people
- Sponsor
- University of Portsmouth
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT03737851
- Testing
- elezanumab
- Where
- 49 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Leukemia
Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)
Quizartinib is an experimental drug. It is not approved for regular use. It can only be used in medical research. Adults might be able to join this study after bone marrow tests show they have a certain kind of blood cancer…
- Trial name
- QuANTUM-First (NCT02668653)
- Testing
- Chemotherapy, Quizartinib
- Where
- 244 sites in United States, Argentina and 26 more
- Volunteers
- 539 people
- Sponsor
- Daiichi Sankyo
COVID19
Study of Plasma Exchange in Severe COVID-19
The rationale in severe COVID19 infection is to undertake PEX to aid reduction of the hyperinflammation and reduce the morbidity and mortality to the lungs, but also systemically, such as the heart, kidneys and brain.
- Trial name
- COVIPLEX (NCT04623255)
- Testing
- OCTAPLAS
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- University College, London
Wounds
Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
The main purpose of this phase III clinical trial was to show safety and efficacy of Oleogel-S10 in accelerating the wound healing of Split-Thickness Skin Graft (STSG) donor sites.
- Trial name
- BSG-12 (NCT01807650)
- Testing
- Oleogel-S10, non-adhesive wound dressing, Non-adhesive wound dressing only
- Where
- 14 sites in France, Greece and 2 more
- Volunteers
- 112 people
- Sponsor
- Birken AG
Multiple Myeloma
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM).
- Trial name
- NCT06504524
- Testing
- Elranatamab, Standard of Care
- Where
- 2 sites in United States, Germany
- Volunteers
- 633 people
- Sponsor
- Pfizer
Atherosclerosis, Myocardial Ischemia
Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)
The study is designed to determine whether vorapaxar, when added to the existing standard of care (eg, aspirin, clopidogrel) for preventing heart attack and stroke in patients with acute coronary syndrome, will yield additional…
- Conditions
- Atherosclerosis, Myocardial Ischemia, Myocardial Infarction
- Trial name
- NCT00527943
- Testing
- Vorapaxar
- Volunteers
- 12,944 people
- Sponsor
- Merck Sharp & Dohme LLC
Wounds
Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)
The main purpose of this phase III clinical trial was to compare intra-individually the efficacy, safety and tolerability of Oleogel-S10 and non-adhesive wound dressing versus non-adhesive wound dressing only in accelerating the…
- Trial name
- NCT01657305
- Testing
- Oleogel-S10, non-adhesive wound dressing, Non-adhesive wound dressing only
- Where
- 24 sites in Austria, Bulgaria and 4 more
- Volunteers
- 107 people
- Sponsor
- Birken AG
Wound of Knee, Wound of Hip
Study to Compare Negative Pressure Wound Therapy or Standard Dressings After Orthopedic Surgery
The aim of this study is to assess the prevention of incision healing complications in patients undergoing Total Knee Arthroscopy (TKA) and Total Hip Arthroscopy (THA) treated with either Single-Use Incisional NPWT (Negative…
- Trial name
- PICO (NCT02064270)
- Testing
- Single-Use Negative Pressure Wound Therapy, Standard postsurgical dressings
- Where
- United States
- Volunteers
- 526 people
- Sponsor
- University of Missouri-Columbia
Obstructive Sleep Apnea, Resistant Hypertension
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
Hypertension affects an estimated 60-70 million Americans, predisposing them to potentially life threatening cardiovascular complications.
- Conditions
- Obstructive Sleep Apnea, Resistant Hypertension, Hyperaldosteronism
- Trial name
- NCT01897727
- Testing
- Spironolactone, BP medication uptitration
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Alabama at Birmingham
Thermal Burns
A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns
This study will be a three-arms study intending to demonstrate superiority of NexoBrid treatment over the Gel Vehicle placebo control treatment and over SOC in thermal burn subjects. The study objectives are: 1.
- Trial name
- NCT02148705
- Testing
- NexoBrid, Standard of Care (SOC), Gel Vehicle
- Where
- 29 sites in United States, Belgium and 6 more
- Volunteers
- 175 people
- Sponsor
- MediWound Ltd
Covid19
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization.
- Trial name
- COPPS (NCT04662073)
- Testing
- Camostat
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Stanford University
Asthma
A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.
The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe…
- Trial name
- ANDHI (NCT03170271)
- Testing
- Benralizumab (Medi-563)
- Where
- 213 sites in United States, Austria and 12 more
- Volunteers
- 660 people
- Sponsor
- AstraZeneca
COVID-19
Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19
Tocilizumab is an effective treatment for severe coronavirus disease 2019 (Covid-19) pneumonia and related inflammation. Given limited global supplies, clarification of the optimal tocilizumab dose is critical.
- Trial name
- COVIDOSE-2 (NCT04479358)
- Testing
- Tocilizumab, Standard of Care
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Lupus Nephritis
A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis
The study aims to evaluate the safety and clinical effect of daily oral treatment with laquinimod capsules in active lupus nephritis participants.
- Trial name
- NCT01085097
- Testing
- Laquinimod, Mycophenolate Mofetil, Prednisolone/Prednisone
- Where
- 30 sites in United States, Canada and 3 more
- Volunteers
- 46 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Foot Ulcer, Diabetic
A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers
The primary objective of this study is to assess the effectiveness of MatriStem devices compared to cellular dermal replacement tissue, for the treatment of non-healing diabetic foot ulcers.
- Trial name
- NCT01858545
- Testing
- MatriStem, Cellular Dermal Replacement Tissue
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Integra LifeSciences Corporation
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Lupus Erythematosus, Systemic
A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus
This current Phase 3 study will evaluate the efficacy and safety of administration of subcutaneous (sc) IPP-201101 in patients with active SLE.
- Trial name
- LUPUZOR (NCT02504645)
- Testing
- IPP-201101, Standard of Care
- Where
- 30 sites in United States, Czechia and 6 more
- Volunteers
- 202 people
- Sponsor
- ImmuPharma
Venous Leg Ulcer, Diabetic Foot Ulcer
Clinical Performance and Cost Effectiveness of Biatain® Silicone Compared With Standard of Care
A randomised controlled investigation comparing the clinical performance and cost effectiveness of Biatain® Silicone with Standard of Care dressing including filler in chronic wounds (CP351 - BISIL Study) This study (BISIL) will…
- Trial name
- BISIL (NCT05786612)
- Testing
- Biatain® Silicone, Mepilex Border with Aquacel Extra Hydrofiber
- Where
- 9 sites in United Kingdom
- Volunteers
- 102 people
- Sponsor
- Coloplast A/S